How to appeal a Blue Cross Blue Shield of Massachusetts multiple myeloma (non-car-t) denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Blue Cross Blue Shield of Massachusetts-specific note: Non-profit; ~3M members. MA has the most expansive state mandated benefits in the US and strong supplemental parity rules. MA OPP (Office of Patient Protection) provides external review separately from carriers — distinct from federal IRO process for fully-insured plans.

What Blue Cross Blue Shield of Massachusetts's policy requires for multiple myeloma (non-car-t)

Cited policy: BCBS Sarclisa (Isatuximab-irfc) for MM

RRMM with IsaPd or IsaKd after ≥1 prior therapy (Pd ≥2 prior including Rev + PI per ICARIA-MM). NDMM-TI: IsaVRd per IMROZ post Sep 2024 FDA approval. Hematologist-oncologist Rx. Q1wk x4 then q2wk; 10 mg/kg IV.

How Blue Cross Blue Shield of Massachusetts denies multiple myeloma (non-car-t) — and how to counter it

Where Blue Cross Blue Shield of Massachusetts pushes back: 1) Too similar to Darzalex — duplicative; 2) Frontline use experimental; 3) Required dara failure first.

Counter-arguments that hold up: Sarclisa binds a DIFFERENT CD38 epitope than Darzalex with distinct FcγR engagement profile. ICARIA-MM (Attal Lancet 2019;394:2096) IsaPd HR 0.596; IKEMA (Moreau Lancet 2021;397:2361) IsaKd HR 0.531; APOLLO (Dimopoulos Lancet Oncol 2021;22:801). IMROZ (Facon NEJM 2024;391:1597) IsaVRd vs VRd NDMM-TI HR 0.60 — basis for FDA frontline NDMM-TI approval Sep 20, 2024. Activity demonstrated in dara-naive AND increasingly dara-refractory subsets.

What Blue Cross Blue Shield of Massachusetts typically denies for multiple myeloma (non-car-t)

Across Blue Cross Blue Shield of Massachusetts's commercial and Medicare books, denials cluster around a small number of patterns. For multiple myeloma (non-car-t), expect:

• MA-specific mandated benefit disputes (most generous in US)
• Behavioral health parity (MA has tighter parity rules than federal MHPAEA)
• Tiered-network provider disputes
• Specialty drug PA

Treatments most often denied in this category

These are the multiple myeloma (non-car-t) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Darzalex IV
• Darzalex Faspro SC
• Sarclisa
• Tecvayli
• Elrexfio
• Talvey

How to submit the appeal to Blue Cross Blue Shield of Massachusetts

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Blue Cross Blue Shield of Massachusetts cited in the denial.
3. File the appeal through Blue Cross Blue Shield of Massachusetts's portal (members: https://home.bluecrossma.com ; providers: https://provider.bluecrossma.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MA, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Blue Cross Blue Shield of Massachusetts's prior-authorization criteria by drug: Blue Cross Blue Shield of Massachusetts PA criteria on ApprovalHelp.